Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.54 |
| ▸ | CXCR3 | P49682 | 16/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637672 | 0.91 | CCR1 (0.63) | CCR1CXCR3CHRM1 | |
| SCHEMBL1637669 | 0.91 | CCR1 (0.63) | CCR1CXCR3CHRM1 | |
| SCHEMBL10063572 | 0.88 | CCR1 (0.66) | CCR1CXCR3 | |
| SCHEMBL12726222 | 0.88 | CXCR3 (0.43) | CCR1CXCR3CHRM1 | |
| SCHEMBL10063575 | 0.88 | CCR1 (0.64) | CCR1CXCR3 | |
| SCHEMBL12726242 | 0.87 | CHRM1 (0.45) | CCR1CXCR3CHRM1 | |
| SCHEMBL12726261 | 0.86 | CXCR3 (0.44) | CCR1CXCR3CHRM1 | |
| SCHEMBL12726180 | 0.86 | CXCR3 (0.45) | CCR1CXCR3CHRM1 | |
| SCHEMBL12726215 | 0.86 | CXCR3 (0.44) | CXCR3CHRM1 | |
| SCHEMBL12726175 | 0.86 | SMO (0.42) | CCR1CXCR3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744822-B2 | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors | CHEMOCENTRYX, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20170290808-A1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CHEMOCENTRYX, INC. | 2017-10-12 | — | — | US | disclosed |
| US-8946240-B2 | 4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines | CHEMOCENTRYX, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130184289-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CHEMOCENTRYX INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130178623-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CHEMOCENTRYX, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8481545-B2 | 3-(imidazolyl)-pyrazolo[3,4-b] pyridines | CHEMOCENTRYX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120010214-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184289-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885CXCR3 11/4885CHRM1 689/4885 |
| US-20170290808-A1 | REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | CCR1, CCRL2, CCR3 | CCR1 1/4885CXCR3 9/4885CHRM1 1452/4885 |
| US-20120010214-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885CXCR3 11/4885CHRM1 689/4885 |
| US-11744822-B2 | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors | CCR1, CCRL2, CCR3 | CCR1 1/4885CXCR3 9/4885CHRM1 1452/4885 |
| US-20130178623-A1 | 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES | CCR1, CCR3, CCR4 | CCR1 1/4885CXCR3 11/4885CHRM1 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.